Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for CancerDecision ResourcesApril 9, 2009 33 Pages - SKU: DECR2219112 |
|
IVD Market Research Bundle (In Vitro Diagnostic Test Markets, BRIC and Other Regional Markets, Biomarker Testing and Other Pharmacodiagnostics)
3/3/2012 | published by: Kalorama Information
What does the diagnostic market look like today, how is the continuing economic news effecting the market, and what are companies doing right now to prosper? This diagnostic industry market research bundle, with over
|
more...
|
$5,995.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Triple Analysis: Melanoma, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated
|
more...
|
$5,175.00
|
Related Markets
- Biotechnology
- Antibody Technologies
- In Vitro Diagnostics
- Immunoassays
- Pharmaceuticals
- Vaccines
- Therapeutic Area
- Oncology/Hematology
Oncology/Hematology Reports
- Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
- Commercializing Biomarkers in Therapeutic and Diagnostic Applications
- Hematological Cancer Therapies
